Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials

Author(s):
Norrby, M.; Vesikari, T.; Lindqvist, L.; Maeurer, M.; Ahmed, R.; Mandavifar, S.; Bennett, S.; McClain, J.B.; Shepherd, B.M.; Li, D.; Hokey, D.A.; Kromann, I.; Hoff, S.T.; Andersen, P.; Visser, A.W. de; Joosten, S.A. (0000-0002-9878-0863); Ottenhoff, T.H.M. (0000-0003-3706-3403); Andersson, J.; Brighenti, S.
Published
2017
Publication type
Article / Letter to editor
TuberculosisVaccineHumanClinical trialSafetyImmunity
Date issued
2017-03-14
Language
English
Is part of
Vaccine (2017), Vol. 35, no. 12, p. 1652-1661
hdl
1887/114401
doi
10.1016/j.vaccine.2017.01.055